Verrica Pharmaceuticals
VRCA
63 hedge funds and large institutions have $84.2M invested in Verrica Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 22 increasing their positions, 7 reducing their positions, and 15 closing their positions.
214% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 7
131% more call options, than puts
Call options by funds: $446K | Put options by funds: $193K
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
7% more funds holding
Funds holding: 59 → 63 (+4)
0.39% more ownership
Funds ownership: 3.09% → 3.48% (+0.39%)
0% more capital invested
Capital invested by funds: $84.2M → $84.2M (+$83.3K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.44M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.87M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$1.85M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.26M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$836K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$1.36M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.2M |
| 3 |
Jane Street
New York
|
-$867K |
| 4 |
Morgan Stanley
New York
|
-$709K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$515K |
VRCA Hedge Fund Activity: Q2 2023 in Review
63 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q2 2023, worth a combined $84.2M — up 0.1% from $84.2M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new VRCA positions and 15 closed out — a net gain of 4 holders — while 22 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $5.44M. The largest seller was EAM Investors, exiting entirely with an estimated $1.36M sold.
- 63 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q2 2023, up from 59 in Q1 2023.
- Funds reported $84.2M of Verrica Pharmaceuticals stock for Q2 2023, up 0.1% quarter-over-quarter.
- 19 funds opened new Verrica Pharmaceuticals positions in Q2 2023 and 15 closed out, a net change of +4 holders.
- The largest Verrica Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $5.44M added.
- The largest Verrica Pharmaceuticals seller in Q2 2023 was EAM Investors, an estimated $1.36M sold.
Based on aggregated 13F filings for Q2 2023.